

P.O. Box 8738, Dayton, OH 45401-8738 | CareSource.com

Re: Summary of PDL Changes Effective July 15, 2024

Dear CareSource Member:

Your health care is our priority. That is why we are writing to tell you that on July 15, 2024, CareSource will change its Preferred Drug List (PDL). A PDL is a list of preferred drugs.

THE FOLLOWING MEDICINES WILL BE PREFERRED ON THE PDL EFFECTIVE JULY 15, 2024.

| Brand Name | Generic Name | Dose(s) | Notes |
|-------------------|-------------------|------------------|-------|
| | Aprepitant | 40 mg capsules | |
| Finacea | Azelaic acid | 15% Foam | |
| Releuko | Filgrastim – ayow | All strengths of | |
| | | injection | |

IF APPLICABLE: THE FOLLOWING MEDICINES WILL BE NON-PREFERRED ON THE PDL EFFECTIVE JULY 15. 2024.

| <u> </u> | | | |
|-------------------|--|-------------------------------|--|
| Brand Name | Generic Name | Dose(s) | Notes |
| Myfembree | Relugolix/ estradiol/ norethindrone | 40 mg/ 1 mg/ 0.5 mg tablet | Update to prior authorization and step therapy |
| Zituvimet | Sitagliptin/ metformin | All strengths of tablet | |

IF APPLICABLE: THE FOLLOWING MEDICINES HAVE A CHANGE IN STATUS EFFECTIVE JULY 15, 2024.

| Brand Name | Generic Name | Dose(s) | Notes |
|------------|----------------------|----------------------------|----------------------------|
| | Baclofen | 10 mg/ 5mL solution | Prior authorization update |
| | Belladonna and Opium | All strengths | Prior authorization update |
| Brixadi | Buprenorphine | All strengths of injection | Update to quantity limits |
| Fabhalta | Iptacopan | 200 mg capsule | Update to quantity limits |
| Flector | Diclofenac | 1.3% (180 mg) patch | Update to quantity limits |

| Forteo | Teriparatide | 250 mcg/ mL injection | Prior authorization update |
|----------------------------|--------------------------------------|---|---|
| Igalmi | Dexmedetomidine | All strengths of film | Prior authorization update |
| Konvomep | omeprazole/ sodium bicarbonate | Suspension | Update to step therapy and quantity limits |
| Licart ER | Diclofenac epolamine | 1.3% patch | Update to quantity limits |
| Narcotic Cough Medications | | All dosage forms and strengths | Prior authorization update |
| | Opium Tincture | All strengths | Prior authorization update |
| Restasis Multidose | Cyclosporine | 0.05% eye drop | Update to quantity limits |
| Tuxarin ER | Codeine/ chlorpheniramine | 40 mg/ 5.6 mg extended-release tablet | Added prior authorization, age limit and quantity limits |
| Tymlos | Abaloparatide | All strengths | Prior authorization update |
| Vevye | Cyclosporine | 0.1 % eye drop | Also added prior authorization |
| Wakix | Pitolisant | All strengths of tablet | Prior authorization update |
| Zoryve | Roflumilast | 0.3% Foam | Added prior authorization |
| Adzynma | ADAMTS13 | All strengths for medical benefit only | Add prior authorization for J3490 effective August 1, 2024 |
| Aldurazyme | Laronidase | All strengths for medical benefit only | Add prior authorization for J7325 effective August 1, 2024 |
| Atryn | Antithrombin alfa | All strengths for medical benefit only | Add prior authorization for J7196 effective August 1, 2024 |
| Avsola | Infliximab | All strengths for medical benefit only | Add prior authorization for Q5121 effective August 1, 2024 |
| Benlysta | Belimumab | All strengths for medical benefit only | Add prior authorization for J0490 effective August 1, 2024 |

| Ceprotin | Protein C concentrate | All strengths for medical benefit only | Add prior authorization for J2724 effective August 1, 2024 |
|-----------------|----------------------------|--|--|
| Cresemba | Isavuconazonium sulfate | All strengths for medical benefit only | Add prior authorization for J1833 effective August 1, 2024 |
| Durysta | Bimatoprost implant | All strengths for medical benefit only | Add prior authorization for J7351 effective August 1, 2024 |
| Elaprase | Idursulfase | All strengths for medical benefit only | Add prior authorization for J1743 effective August 1, 2024 |
| Fulphila | Pegfilgrastim | All strengths for medical benefit only | Add prior authorization for Q5108 effective August 1, 2024 |
| Givlaari | Givosiran | All strengths for medical benefit only | Add prior authorization for J0223 effective August 1, 2024 |
| Herzuma | Trastuzumab | All strengths for medical benefit only | Add prior authorization for Q5113 effective August 1, 2024 |
| iDose TR | Travoprost implant | All strengths for medical benefit only | Add prior authorization for J3490 effective August 1, 2024 |
| Inflectra | Infliximab | All strengths for medical benefit only | Add prior authorization for Q5103 effective August 1, 2024 |
| Immune Globulin | | All strengths for medical benefit only | Add prior authorization for J1599, J1556, J1567, J1569, J1561, J1557, J1568, J1576, J1459, J1551, J1555, J1559, J1575, J1558 effective August 1, 2024 |
| Mepsevii | Vestronidase alfa- vjbk | All strengths for medical benefit only | Add prior authorization for J3397 effective August 1, 2024 |
| Naglazyme | Galsulfase | All strengths for medical benefit only | Add prior authorization for J1458 effective August 1, 2024 |
| Neulasta | Pegfilgrastim | All strengths for medical benefit only | Add prior authorization for J2506 effective August 1, 2024 |

| Nyvepria | Pegfilgrastim | All strengths for medical benefit only | Add prior authorization for Q5122 effective August 1, 2024 |
|-------------|---------------|--|---|
| Ogivri | Trastuzumab | All strengths for medical benefit only | Add prior authorization for Q5114 effective August 1, 2024 |
| Ontruzant | Trastuzumab | All strengths for medical benefit only | Add prior authorization for Q5112 effective August 1, 2024 |
| Oxlumo | Lumasiran | All strengths for medical benefit only | Add prior authorization for J0224 effective August 1, 2024 |
| Panhematin | Hemin | All strengths for medical benefit only | Add prior authorization for J1640 effective August 1, 2024 |
| Reblozyl | Luspatercept | All strengths for medical benefit only | Add prior authorization for J0896 effective August 1, 2024 |
| Remicade | Infliximab | All strengths for medical benefit only | Add prior authorization for J1745 effective August 1, 2024 |
| Renflexis | Infliximab | All strengths for medical benefit only | Add prior authorization for Q5104 effective August 1, 2024 |
| Rivfloza | Nedosiran | All strengths for medical benefit only | Add prior authorization for J3490 effective August 1, 2024 |
| Saphnelo | Anifrolumab | All strengths for medical benefit only | Add prior authorization for J0491 effective August 1, 2024 |
| Sunleca | Lenacapavir | All strengths for medical benefit only | Add prior authorization for J1961 effective August 1, 2024 |
| Trastuzumab | Herceptin | All strengths for medical benefit only | Add prior authorization for J9355 and J9356 effective August 1, 2024 |
| Trazimera | Trastuzumab | All strengths for medical benefit only | Add prior authorization for Q5116 effective August 1, 2024 |

| Trogarzo | Ibalizumab | All strengths for medical benefit only | Add prior authorization for J1746 effective August 1, 2024 |
|-----------|-----------------|--|--|
| Udenyca | Pegfilgrastin | All strengths for medical benefit only | Add prior authorization for Q5111 effective August 1, 2024 |
| Vimizim | Elosulfase alfa | All strengths for medical benefit only | Add prior authorization for J1322 effective August 1, 2024 |
| Ziextenzo | Pegfilgrastim | All strengths for medical benefit only | Add prior authorization for Q5120 effective August 1, 2024 |

What should you do?

First, talk to your prescriber. There may be other medicines on the CareSource PDL that you can take instead. There are a few ways you and your prescriber can find medicines:

- You can look on our website at **CareSource.com**. On the Members page, go to Tools & Resources and click on "Find My Prescriptions".
- Or, call our Member Services Department at **1-844-607-2829** (TTY: 1-800-743-3333 or 711).

We are here to help you. The Member Services Department is open Monday through Friday, 8 a.m. to 8 p.m. Eastern Time.

Sincerely,

CareSource

RR2022-IN-MMED-1895-V.9; First Use: 11/29/2022 OMPP Approved: 11/29/2022